Equities

Dextech Medical AB

Dextech Medical AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)4.44
  • Today's Change-0.16 / -3.48%
  • Shares traded4.28k
  • 1 Year change-3.90%
  • Beta1.1105
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments192535
Total Receivables, Net0.640.110.20
Total Inventory------
Prepaid expenses--0.470.35
Other current assets, total------
Total current assets202636
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net119.213.56
Long term investments0.000.000.00
Note receivable - long term------
Other long term assets------
Total assets313540
LIABILITIES
Accounts payable--0.150.25
Accrued expenses--0.550.43
Notes payable/short-term debt--00
Current portion long-term debt/capital leases------
Other current liabilities, total0.980.020.03
Total current liabilities0.980.720.71
Total long term debt--00
Total debt--00
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities0.980.720.71
SHAREHOLDERS EQUITY
Common stock--0.830.83
Additional paid-in capital--105105
Retained earnings (accumulated deficit)--(81)(71)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total309.213.56
Total equity303439
Total liabilities & shareholders' equity313540
Total common shares outstanding181818
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.